Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4] by Year
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M) ($M)
Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4]: $198M in FY2024, down 82.3% from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-13) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 29, 2024 | 198 | -82.3% | Form 10-K (filed 2025-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 1,117 | -45.8% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Jan 1, 2023 | 2,059 | +17.6% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 1,751 | – | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 0 | – | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 0 | – | Form 10-K (filed 2022-02-17) ↗ |
Breakdown
What makes up COVID-19 Vaccine [reported through FY2024Q4]
Cite this data
StockData. (2026). Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4] ($M), annual FY2019–FY2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-covid19-intl
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.